Vericel Co. (NASDAQ:VCEL) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC grew its stake in shares of Vericel Co. (NASDAQ:VCELGet Rating) by 52.3% in the second quarter, according to its most recent filing with the SEC. The fund owned 9,974 shares of the biotechnology company’s stock after acquiring an additional 3,424 shares during the period. SG Americas Securities LLC’s holdings in Vericel were worth $251,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Arizona State Retirement System lifted its position in shares of Vericel by 6.1% during the 2nd quarter. Arizona State Retirement System now owns 11,418 shares of the biotechnology company’s stock valued at $288,000 after acquiring an additional 661 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Vericel during the 2nd quarter valued at $350,000. KBC Group NV acquired a new stake in Vericel during the 2nd quarter valued at $110,000. Scout Investments Inc. raised its stake in Vericel by 2.8% during the 2nd quarter. Scout Investments Inc. now owns 355,989 shares of the biotechnology company’s stock valued at $8,964,000 after purchasing an additional 9,592 shares during the period. Finally, State of Alaska Department of Revenue raised its stake in Vericel by 9.2% during the 2nd quarter. State of Alaska Department of Revenue now owns 35,642 shares of the biotechnology company’s stock valued at $897,000 after purchasing an additional 2,990 shares during the period.

Vericel Trading Down 23.4 %

NASDAQ VCEL opened at $17.65 on Thursday. Vericel Co. has a 1-year low of $17.30 and a 1-year high of $46.30. The company has a market capitalization of $832.69 million, a PE ratio of -49.03 and a beta of 1.99. The firm’s fifty day simple moving average is $24.55 and its 200-day simple moving average is $26.60.

Wall Street Analysts Forecast Growth

VCEL has been the topic of several recent analyst reports. Truist Financial downgraded shares of Vericel from a “buy” rating to a “hold” rating in a research note on Wednesday. Stephens initiated coverage on shares of Vericel in a research note on Thursday, October 13th. They set an “overweight” rating and a $40.00 target price on the stock. StockNews.com started coverage on shares of Vericel in a research note on Wednesday, October 12th. They set a “sell” rating on the stock. Finally, BTIG Research downgraded shares of Vericel from a “buy” rating to a “neutral” rating in a research note on Wednesday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $38.00.

About Vericel

(Get Rating)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.

Featured Articles

Institutional Ownership by Quarter for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.